SpringerLink
Log in

Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies

  • Review
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background

Hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) following cytoreductive surgery (CRS) has been applied for peritoneal metastasis (PM) from colorectal cancer (CRC). This study aimed to compare oxaliplatin (OX) with mitomycin C (MMC) in HIPEC for PM from CRC in surgical and survival outcomes.

Methods

A systematic literature search was performed in PubMed and Ovid databases for studies comparing OX with MMC in HIPEC for PM from CRC. The last search was performed on June 21, 2020.

Results

Eleven articles published between 2006 and 2020 with 2091 patients were included. When compared with MMC group, the OX group showed significantly higher rate of major complications (P = 0.006, OR = 1.57, 95% CI [1.14, 2.16], I2 = 0%). Besides, no significant difference was observed between the two groups for survival outcomes, regardless of 3-year overall survival (P = 0.98, OR = 1.00, 95% CI [0.83, 1.22], I2 = 0%), 3-year disease-free survival (P = 0.98, OR = 1.00, 95% CI [0.83, 1.22], I2 = 0%), or 5-year overall survival (P = 0.91, OR = 1.01, 95% CI [0.81, 1.26], I2 = 0%).

Conclusion

OX and MMC could achieve comparable survival in HIPEC for PM from CRC. However, in consideration of the high incidence of major complication in OX group, MMC might be the safer one in clinical routines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

    PubMed  Google Scholar 

  2. Pinto A, Pocard M (2019) Hyperthermic intraperitoneal chemotherapy with cisplatin and mitomycin C for colorectal cancer peritoneal metastases: a systematic review of the literature. Pleura Peritoneum 4(2):20190006

    Article  PubMed  PubMed Central  Google Scholar 

  3. Roh SJ, Park SC, Choi J, Lee JS, Lee DW, Hong CW, Han KS, Park HC, Sohn DK, Oh JH (2020) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin C used for colorectal peritoneal carcinomatosis. Ann Coloproctol 36(1):22–29

    Article  PubMed  PubMed Central  Google Scholar 

  4. Narasimhan V, Tan S, Kong J, Pham T. (2020) Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis.

  5. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 21(20):3737–3743

    Article  Google Scholar 

  6. Eng OS, Turaga KK (2019) Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer. J Surg Oncol 119(5):613–615

    Article  PubMed  Google Scholar 

  7. Guo Y, **ong BH, Zhang T, Cheng Y, Ma L (2016) XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Investig 34(2):94–104

    Article  CAS  Google Scholar 

  8. Ceelen W (2019) HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road?, European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 45(3):400–402

  9. Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. (2018) A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol Conf.;36(18 Supplement 1).

  10. Feroci F, Lenzi E, Garzi A, Vannucchi A, Cantafio S, Scatizzi M (2013) Intracorporeal versus extracorporeal anastomosis after laparoscopic right hemicolectomy for cancer: a systematic review and meta-analysis. Int J Color Dis 28(9):1177–1186

    Article  Google Scholar 

  11. Elekonawo FMK (2020) 纳入Effect of intraperitoneal chemotherapy concentration on morbidity and survival. J Surg Oncol 4(2):293–300

    CAS  Google Scholar 

  12. Glockzin G, von Breitenbuch P, Schlitt HJ, Piso P (2013) Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis. J Surg Oncol 107(6):574–578

    Article  CAS  PubMed  Google Scholar 

  13. Hompes D, D'Hoore A, Wolthuis A, Fieuws S, Mirck B, Bruin S, Verwaal V (2014) The use of oxaliplatin or mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. J Surg Oncol 109(6):527–532

    Article  CAS  PubMed  Google Scholar 

  14. Leung V, Huo YR, Liauw W, Morris DL (2017) Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 43(1):144–149

    Article  CAS  Google Scholar 

  15. Narasimhan V, Warrier S, Michael M, Ramsay R, Heriot A. (2019) Oxaliplatin versus mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study. J Gastrointest Surg: official journal of the Society for Surgery of the Alimentary Tract.

  16. Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spiliotis J, Torres-Melero J, Turaga K, Trout R (2014) The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol 110(7):779–785

    Article  CAS  PubMed  Google Scholar 

  17. Rouers A, Laurent S, Detroz B, Meurisse M (2006) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: higher complication rate for oxaliplatin compared to mitomycin C. Acta Chir Belg 106(3):302–306

    Article  CAS  PubMed  Google Scholar 

  18. van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ (2018) Safety of intraperitoneal mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 44(2):220–227

    Article  Google Scholar 

  19. Votanopoulos K, Ihemelandu C, Shen P, Stewart J, Russell G, Levine EA (2013) A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res 179(1):e133–e139

    Article  CAS  PubMed  Google Scholar 

  20. Woeste MR, Philips P, Egger ME, Scoggins CR, McMasters KM, Martin RCG. (2020) Optimal perfusion chemotherapy: a prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer.

  21. Bakkers C, van Erning FN, Rovers KP, Nienhuijs SW, Burger JW, Lemmens VE, et al. (2020) Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: a nationwide comparative study. Eur J Surg Oncol: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

  22. Wisselink DD, Braakhuis LLF, Gallo G, van Grevenstein WMU, van Dieren S, Kok NFM, de Reuver PR, Tanis PJ, de Hingh IHJT (2019) Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer. Crit Rev Oncol Hematol 142:119–129

    Article  PubMed  Google Scholar 

  23. Wiseman JT, Kimbrough C, Beal EW, Zaidi MY, Staley CA, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Powers B, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, Lee B, Fackche N, Greer J, Pawlik TM, Abdel-Misih S, Cloyd JM (2020) Predictors of anastomotic failure after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: does technique matter? Ann Surg Oncol 27(3):783–792

    Article  PubMed  Google Scholar 

  24. Chouliaras K, Levine EA, Fino N, Shen P, Votanopoulos KI (2017) Prognostic factors and significance of gastrointestinal leak after cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 24(4):890–897

    Article  PubMed  Google Scholar 

  25. Yang J, Chen Q, **dou L, Cheng Y. (2020) The influence of anastomotic leakage for rectal cancer oncologic outcome: a systematic review and meta-analysis.

  26. Torphy RJ, Stewart C, Sharma P, Halpern AL, Oase K, Herter W, Bartsch C, Friedman C, del Chiaro M, Schulick RD, Gleisner A, McCarter MD, Ahrendt SA (2020) Dextrose-containing carrier solution for hyperthermic intraperitoneal chemotherapy: increased intraoperative hyperglycemia and postoperative complications. Ann Surg Oncol

  27. Rovers KP, Bakkers C, Simkens G, Burger JWA, Nienhuijs SW, Creemers GM et al (2019) Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer 19(1):390

    Article  PubMed  PubMed Central  Google Scholar 

  28. Baratti D, Kusamura S, Azmi N, Guaglio M, Montenovo M, Deraco M (2020) Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without mitomycin C-based HIPEC: a comparative study using the peritoneal surface disease severity score (PSDSS). Ann Surg Oncol 27(1):98–106

    Article  PubMed  Google Scholar 

Download references

Funding

This work was supported by the 1·3·5 project for disciplines of excellence—Clinical Research Incubation Project, West China Hospital, Sichuan University (No. 2019HXFH031).

Author information

Author notes

  1. Xubing Zhang, Qingbin Wu, Mingtian Wei and **angbing Deng contributed equally to this work.

Authors and Affiliations

  1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Guo Xue **ang No. 37, Chengdu, 610041, China

    Xubing Zhang, Qingbin Wu, Mingtian Wei, **angbing Deng, Chaoyang Gu & Ziqiang Wang

Authors
  1. Xubing Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qingbin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mingtian Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. **angbing Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chaoyang Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ziqiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ziqiang Wang.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 20 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, X., Wu, Q., Wei, M. et al. Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies. Int J Colorectal Dis 35, 1831–1839 (2020). https://doi.org/10.1007/s00384-020-03702-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-020-03702-y

Keywords

Search

Navigation